| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Dianthus Therapeutics, Inc. (DNTH) has 5 insiders with recent SEC Form 4 filings, including 1 buy and 12 sells. DNTH is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CFO | 89.7K | $7.40M | - | |
| Other | 16.2K | $1.33M | - | |
| VP | 8.0K | $659.8K | -26,530 | |
| Dir | 0 | - | - | |
| CEO | 0 | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 12, 2019 | Cooke Michael P. | Chief Scientific Officer | Sell | 844 | $12.00 | $10,128.00 | -0.3% | |
| Sep 3, 2019 | Cooke Michael P. | Chief Scientific Officer | Sell | 5,000 | $10.11 | $50,531.00 | -1.8% | |
| Aug 1, 2019 | Cooke Michael P. | Chief Scientific Officer | Sell | 7,500 | $13.42 | $100,631.00 | -1.4% | |
| Jul 1, 2019 | Cooke Michael P. | Chief Scientific Officer | Sell | 7,500 | $14.40 | $107,983.00 | -1.3% | |
| Jun 21, 2019 | Isacson Christina K. | Chief Business Officer | Sell | 5,415 | $16.07 | $87,019.05 | -5.2% | |
| Jun 21, 2019 | Gardner Jason | See Remarks | Sell | 14,000 | $15.11 | $211,523.31 | -1.9% | |
| Jun 17, 2019 | Cooke Michael P. | Chief Scientific Officer | Sell | 7,500 | $13.90 | $104,267.25 | -2.6% | |
| Mar 20, 2019 | Booth Bruce70 | Director | Sell | 14,245 | $17.86 | $254,415.70 | -100% | |
| Mar 20, 2019 | Atlas Venture Fund X, L.P.69 | 10% Owner | Sell | 14,245 | $17.86 | $254,415.70 | -100% | |
| Jun 25, 2018 | Gardner Jason | See Remarks | Buy | 400 | $15.00 | $6,000.00 | +0.1% |